Compare IOVA & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | FORTY |
|---|---|---|
| Founded | 2007 | 1985 |
| Country | United States | Israel |
| Employees | N/A | 19337 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2008 | 1998 |
| Metric | IOVA | FORTY |
|---|---|---|
| Price | $14.29 | $114.99 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 11.4M | 2.1K |
| Earning Date | 05-07-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 1.32% |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.74 | N/A |
| Revenue Next Year | $40.31 | N/A |
| P/E Ratio | ★ N/A | $36.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $102.01 |
| 52 Week High | $11.17 | $190.56 |
| Indicator | IOVA | FORTY |
|---|---|---|
| Relative Strength Index (RSI) | 85.96 | 48.29 |
| Support Level | $3.57 | $109.49 |
| Resistance Level | N/A | $119.68 |
| Average True Range (ATR) | 0.67 | 1.67 |
| MACD | 0.27 | 0.09 |
| Stochastic Oscillator | 99.84 | 34.78 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.